Fingerprint
Dive into the research topics where Arash Hatefi is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Projects
- 6 Finished
-
Trispecific Killer Cell Engager for the Treatment of Systemic Lupus Erythematosus
Hatefi, A. (PI)
National Institute of Allergy and Infectious Diseases
4/9/25 → 3/31/26
Project: Research project
-
Stem Cell-based Platform for Targeted Enzyme/Prodrug Therapy of Recurrent Ovarian Cancer
Hatefi, A. (PI) & Hatefi, A. A. (CoPI)
4/1/21 → 3/31/26
Project: Research project
-
A Nanotechnology Platform for Suicide Gene Therapy of Recurring Ovarian Cancer
Hatefi, A. (PI)
4/1/15 → 3/31/21
Project: Research project
-
Bioengineering a Safe and Efficient Vector Technology for Stem Cell Transfection
Hatefi, A. (PI)
National Institute of Biomedical Imaging and Bioengineering
5/15/14 → 10/31/17
Project: Research project
-
Development of a Nanotechnology Platform for Prostate Cancer Gene Therapy
Hatefi, A. (PI)
1/1/08 → 12/31/08
Project: Research project
-
Engineered tumor-tropic mesenchymal stem cells as targeted therapeutic delivery systems for refractory Ovarian cancer
Li, G., Massumi, M., Owji, H., Yang, G., Girda, E. & Hatefi, A., Feb 10 2026, In: Journal of Controlled Release. 390, 114584.Research output: Contribution to journal › Article › peer-review
Open Access -
A high affinity and specificity anti-HER2 single-domain antibody (VHH) that targets trastuzumab’s epitope with versatile biochemical, biological, and medical applications
Nikkhoi, S. K., Heydarzadeh, H., Vandavasi, V. G., Yang, G., Louro, P., Polunas, M., Owji, H. & Hatefi, A., Feb 2024, In: Immunologic Research. 72, 1, p. 103-118 16 p.Research output: Contribution to journal › Article › peer-review
Open Access8 Link opens in a new tab Scopus citations -
A Novel Tetravalent Bispecific Immune Cell Engager Activates Natural Killer Cells to Kill Cancer Cells without Mediating Fratricide
Yang, G., Nikkhoi, S. K., Owji, H., Li, G., Massumi, M., Cervelli, J., Vandavasi, V. G. & Hatefi, A., Sep 2024, In: Antibodies. 13, 3, 75.Research output: Contribution to journal › Article › peer-review
Open Access1 Link opens in a new tab Scopus citations -
A quantitative MRI-based approach to estimate the permeation and retention of nanomedicines in tumors
Nomani, A., Yousefi, S., Sargsyan, D. & Hatefi, A., Apr 2024, In: Journal of Controlled Release. 368, p. 728-739 12 p.Research output: Contribution to journal › Article › peer-review
Open Access28 Link opens in a new tab Scopus citations -
Bispecific immune cell engager enhances the anticancer activity of CD16+ NK cells and macrophages in vitro, and eliminates cancer metastasis in NK humanized NOG mice
Khoshtinat Nikkhoi, S., Yang, G., Owji, H., Grizotte-Lake, M., Cohen, R. I., Gil Gonzalez, L., Massumi, M. & Hatefi, A., Mar 15 2024, In: Journal for ImmunoTherapy of Cancer. 12, 3, e008295.Research output: Contribution to journal › Article › peer-review
Open Access15 Link opens in a new tab Scopus citations